Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study
- 1 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Endocrinological Investigation
- Vol. 43 (11), 1613-1622
- https://doi.org/10.1007/s40618-020-01246-0
Abstract
Purpose Cushing's disease (CD) is associated with significant clinical burden, increased mortality risk, and impaired health-related quality of life (HRQoL). This analysis explored the effect of long-acting pasireotide on clinical signs of hypercortisolism and HRQoL in a large subset of patients with CD. Methods In this phase III study (clinicaltrials.gov: NCT01374906), 150 adults with CD and a mean urinary free cortisol (mUFC) level between 1.5 and 5.0 times the upper limit of normal (ULN) started long-acting pasireotide 10 or 30 mg every 28 days with dose increases/decreases permitted based on mUFC levels/tolerability (minimum/maximum dose: 5/40 mg). Changes in clinical signs of hypercortisolism and HRQoL were assessed over 12 months of treatment and were stratified by degree of mUFC control for each patient. Results Patients with controlled mUFC at month 12 (n = 45) had the greatest improvements from baseline in mean systolic (- 8.4 mmHg [95% CI - 13.9, - 2.9]) and diastolic blood pressure (- 6.0 mmHg [- 10.0, - 2.0]). Mean BMI, weight, and waist circumference improved irrespective of mUFC control. Significant improvements in CushingQoL total score of 5.9-8.3 points were found at month 12 compared with baseline, irrespective of mUFC control; changes were driven by improvements in physical problem score, with smaller improvements in psychosocial score. Conclusions Long-acting pasireotide provided significant improvements in clinical signs and HRQoL over 12 months of treatment, which, in some cases, occurred regardless of mUFC control. Long-acting pasireotide represents an effective treatment option and provides clinical benefit in patients with CD.Funding Information
- Novartis Pharma AG (-)
This publication has 31 references indexed in Scilit:
- Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trialThe Lancet Diabetes & Endocrinology, 2017
- Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort studyThe Lancet Diabetes & Endocrinology, 2016
- Complications of Cushing's syndrome: state of the artThe Lancet Diabetes & Endocrinology, 2016
- Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2015
- The Treatment of Cushing's DiseaseEndocrine Reviews, 2015
- Cushing's syndromeThe Lancet, 2015
- MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspectsActa Endocrinologica, 2012
- A 12-Month Phase 3 Study of Pasireotide in Cushing's DiseaseThe New England Journal of Medicine, 2012
- SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileActa Endocrinologica, 2002
- Morbidity and mortality in Cushing's disease: an epidemiological approachClinical Endocrinology, 1994